FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366367886> ?p ?o ?g. }

• W4366367886 endingPage "1110" @default.
• W4366367886 startingPage "1099" @default.
• W4366367886 abstract "Is it economically worthwhile to use GnRH agonist (GnRHa) to prevent menopausal symptoms (MS) and protect fertility in premenopausal women with breast cancer (BC) during chemotherapy from the US perspective?It is cost-effective to administer GnRHa during chemotherapy in order to forefend MS in premenopausal patients with BC when the willingness-to-pay (WTP) threshold is $50 000.00 per quality-adjusted life-year (QALY), and to preserve fertility in young patients with BC who undergo oocyte cryopreservation (OC), or no OC, when the WTP thresholds per live birth are $71 333.33 and $61 920.00, respectively.Chemotherapy often results in premature ovarian insufficiency (POI) in premenopausal survivors of BC, causing MS and infertility. Administering GnRHa during chemotherapy has been recommended for ovarian function preservation by international guidelines.Two decision-analytic models were developed, respectively, for preventing MS and protecting fertility over a 5-year period, which compared the cost-effectiveness of two strategies: adding GnRHa during chemotherapy (GnRHa plus Chemo) or chemotherapy alone (Chemo).The participants were early premenopausal women with BC aged 18-49 years who were undergoing chemotherapy. Two decision tree models were constructed: one for MS prevention and one for fertility protection from the US perspective. All data were obtained from published literature and official websites. The models' primary outcomes included QALYs and incremental cost-effectiveness ratios (ICERs). The robustness of the models was tested by sensitivity analyses.In the MS model, GnRHa plus Chemo resulted in an ICER of $17 900.85 per QALY compared with Chemo, which was greater than the WTP threshold of $50 000.00 per QALY; therefore, GnRHa plus Chemo was a cost-effective strategy for premenopausal women with BC in the USA. Probabilistic sensitivity analysis (PSA) results showed an 81.76% probability of cost-effectiveness in the strategy. In the fertility model, adding GnRHa for patients undergoing OC and those who were unable to undergo OC resulted in ICERs of $67 933.50 and $60 209.00 per live birth in the USA, respectively. PSA indicated that GnRHa plus Chemo was more likely to be cost-effective over Chemo when the WTP for an additional live birth exceed $71 333.33 in Context I (adding GnRHa to preserve fertility in young patients with BC after OC) and $61 920.00 in Context II (adding GnRHa to preserve fertility in young patients with BC who cannot accept OC).The indirect costs, such as disease-related mental impairment and non-medical costs (e.g. transportation cost) were not included. All data were derived from previously published literature and databases, which might yield some differences from the real world. In addition, the POI-induced MS with a lower prevalence and the specific strategy of chemotherapy were not considered in the MS model, and the 5-year time horizon for having a child might not be suitable for all patients in the fertility model.When considering the economic burden of cancer survivors, the results of this study provide an evidence-based reference for clinical decision-making, showing that it is worthwhile to employ GnRHa during chemotherapy to prevent MS and preserve fertility.This work was supported by the Natural Science Foundation of Fujian Province [2021J02038]; and the Startup Fund for Scientific Research, Fujian Medical University [2021QH1059]. All authors declare no conflict of interest.N/A." @default.
• W4366367886 created "2023-04-21" @default.
• W4366367886 creator A5006756737 @default.
• W4366367886 creator A5011615604 @default.
• W4366367886 creator A5017453632 @default.
• W4366367886 creator A5020232250 @default.
• W4366367886 creator A5031465004 @default.
• W4366367886 creator A5033096447 @default.
• W4366367886 creator A5059392900 @default.
• W4366367886 creator A5082951115 @default.
• W4366367886 date "2023-04-19" @default.
• W4366367886 modified "2023-09-26" @default.
• W4366367886 title "Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer" @default.
• W4366367886 cites W1761951195 @default.
• W4366367886 cites W1907041088 @default.
• W4366367886 cites W1958561554 @default.
• W4366367886 cites W1985650168 @default.
• W4366367886 cites W2033707936 @default.
• W4366367886 cites W2049933754 @default.
• W4366367886 cites W2061713380 @default.
• W4366367886 cites W2063500255 @default.
• W4366367886 cites W2079906731 @default.
• W4366367886 cites W2080471799 @default.
• W4366367886 cites W2088885993 @default.
• W4366367886 cites W2111224984 @default.
• W4366367886 cites W2128911553 @default.
• W4366367886 cites W2151944946 @default.
• W4366367886 cites W2167612570 @default.
• W4366367886 cites W2220296590 @default.
• W4366367886 cites W2408550433 @default.
• W4366367886 cites W2413293160 @default.
• W4366367886 cites W2547588948 @default.
• W4366367886 cites W2597096786 @default.
• W4366367886 cites W2625355327 @default.
• W4366367886 cites W2736215403 @default.
• W4366367886 cites W2750430339 @default.
• W4366367886 cites W2787556478 @default.
• W4366367886 cites W2795588819 @default.
• W4366367886 cites W2802421801 @default.
• W4366367886 cites W2902215430 @default.
• W4366367886 cites W2943435839 @default.
• W4366367886 cites W2946139922 @default.
• W4366367886 cites W2970425800 @default.
• W4366367886 cites W2978115783 @default.
• W4366367886 cites W2981191588 @default.
• W4366367886 cites W2986916985 @default.
• W4366367886 cites W2987085499 @default.
• W4366367886 cites W3023590090 @default.
• W4366367886 cites W3036036520 @default.
• W4366367886 cites W3044605555 @default.
• W4366367886 cites W3048455133 @default.
• W4366367886 cites W3088686555 @default.
• W4366367886 cites W3089922486 @default.
• W4366367886 cites W3128646645 @default.
• W4366367886 cites W3162510283 @default.
• W4366367886 cites W3198893692 @default.
• W4366367886 cites W4200403864 @default.
• W4366367886 doi "https://doi.org/10.1093/humrep/dead073" @default.
• W4366367886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37075316" @default.
• W4366367886 hasPublicationYear "2023" @default.
• W4366367886 type Work @default.
• W4366367886 citedByCount "1" @default.
• W4366367886 countsByYear W43663678862023 @default.
• W4366367886 crossrefType "journal-article" @default.
• W4366367886 hasAuthorship W4366367886A5006756737 @default.
• W4366367886 hasAuthorship W4366367886A5011615604 @default.
• W4366367886 hasAuthorship W4366367886A5017453632 @default.
• W4366367886 hasAuthorship W4366367886A5020232250 @default.
• W4366367886 hasAuthorship W4366367886A5031465004 @default.
• W4366367886 hasAuthorship W4366367886A5033096447 @default.
• W4366367886 hasAuthorship W4366367886A5059392900 @default.
• W4366367886 hasAuthorship W4366367886A5082951115 @default.
• W4366367886 hasConcept C121608353 @default.
• W4366367886 hasConcept C126322002 @default.
• W4366367886 hasConcept C131872663 @default.
• W4366367886 hasConcept C143998085 @default.
• W4366367886 hasConcept C2776600139 @default.
• W4366367886 hasConcept C2776694085 @default.
• W4366367886 hasConcept C2777688143 @default.
• W4366367886 hasConcept C2777904497 @default.
• W4366367886 hasConcept C2779234561 @default.
• W4366367886 hasConcept C2908647359 @default.
• W4366367886 hasConcept C2911206770 @default.
• W4366367886 hasConcept C29456083 @default.
• W4366367886 hasConcept C518429986 @default.
• W4366367886 hasConcept C530470458 @default.
• W4366367886 hasConcept C54355233 @default.
• W4366367886 hasConcept C71924100 @default.
• W4366367886 hasConcept C86803240 @default.
• W4366367886 hasConcept C99454951 @default.
• W4366367886 hasConceptScore W4366367886C121608353 @default.
• W4366367886 hasConceptScore W4366367886C126322002 @default.
• W4366367886 hasConceptScore W4366367886C131872663 @default.
• W4366367886 hasConceptScore W4366367886C143998085 @default.
• W4366367886 hasConceptScore W4366367886C2776600139 @default.
• W4366367886 hasConceptScore W4366367886C2776694085 @default.
• W4366367886 hasConceptScore W4366367886C2777688143 @default.
• W4366367886 hasConceptScore W4366367886C2777904497 @default.

• next